Mass Spectrometry as a Disruptive Technology for Emerging Biotherapeutic Modalities
Cell and gene therapies (CGT) promise to become revolutionary curative treatments, yet realization of this potential requires advances in biomolecular understanding to be on par with quality standards of today’s state-of-the art treatments (e.g. monoclonal antibodies).
Molecular complexity is magnified significantly in CGT, as is the need to pursue adaptation, targeted innovation, and implementation of high-resolution analytical measurement approaches to further the understanding and development of these novel modalities.
This talk will describe translation of principles of the multi-attribute mass spectrometry method (MAM) toward identification and control of quality attributes of emerging therapeutic modalities.
- Gain insight about the unique analytical challenges presented by next generation biotherapeutics
- Learn how multi-attribute mass spectrometry can address key biopharma industry requirements
- Explore how the principles of MAM, including attribute control and new peak detection, can support next generation biotherapeutic development
- John Schiel, Ph.D., Research Chemist, NIST